Today: 7 February 2026
Subscribe
Browse Category

NYSE:NVO News 26 November 2025 - 5 January 2026

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly stock slides as Novo’s Wegovy pill hits U.S. shelves and stokes obesity-drug pricing fears

Eli Lilly shares dropped 3.4% to $1,043.14 after Novo Nordisk launched U.S. sales of an oral Wegovy weight-loss pill starting at $149 a month. Novo’s move intensified focus on pricing in the obesity drug market. The Health Care Select Sector SPDR ETF fell 1.3%, while Novo Nordisk shares rose 2.9%. Investors are awaiting Lilly’s next earnings update on February 4.
5 January 2026
···
Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly stock today: LLY slips as China Mounjaro cuts and U.S. pricing reset draw focus

Eli Lilly shares slipped 0.1% to $1,078.95 by early afternoon Wednesday after reports of price cuts for its diabetes and obesity drugs in China and a planned U.S. list-price reset. A regulatory filing showed Lilly Endowment, the company’s largest shareholder, trimmed its stake slightly. Investors focused on pricing pressure as the company’s GLP-1 drugs face broader access and lower prices heading into 2026.
31 December 2025
···
Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers stock dips in premarket as GLP-1 drug pricing pressure stays in focus

Hims & Hers Health shares fell 0.5% to $32.87 in premarket trading Wednesday after closing down 3.1% the previous session. The move follows price cuts by Novo Nordisk and Eli Lilly on obesity drugs in China, raising questions about future margins and demand for GLP-1 therapies. Hims recently launched its weight-loss membership in the UK, offering access to Wegovy and Mounjaro.
31 December 2025
····
Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

Eli Lilly stock ticks up after hours as China price cuts put Mounjaro, Wegovy in focus

NEW YORK, December 30, 2025, 5:08 PM ET — After-hours Eli Lilly shares were up 0.1% in after-hours trading on Tuesday at $1,079.75 after a Reuters report said it and Novo Nordisk are lowering prices of their top-selling obesity drugs in China. Reuters The pricing move matters because investors have treated Lilly’s obesity franchise as a main growth engine, helping support a premium valuation. A sharper-than-expected push to discount in large markets can pressure margins, even if it expands the customer base. It also lands as drugmakers pivot toward cash-pay channels — patients paying out of pocket, rather than relying
30 December 2025
···
Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk halves Wegovy prices in parts of China as copycat competition looms

Novo Nordisk is cutting Wegovy prices in China, with local reports citing 48% reductions for the highest doses in Yunnan and Sichuan. The move comes as the company faces a 2026 patent expiry for semaglutide and rising competition from Chinese drugmakers. Novo shares fell after the China pricing news circulated. The company did not disclose exact new prices in its statement.
30 December 2025
·
Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

Novo Nordisk Stock (NVO): Wegovy Pill FDA Approval, CagriSema Filing, and the 2026 Outlook Investors Are Watching (Dec. 25, 2025)

December 25, 2025 — Christmas Day is a market holiday in the U.S., but Novo Nordisk A/S is still doing what it’s done for most of the past two years: pulling attention (and capital) toward anything labeled GLP‑1. NASDAQ Trader The headline catalyst is straightforward and extremely investable: the U.S. FDA has approved Novo Nordisk’s Wegovy pill, making it the first oral GLP‑1 treatment approved for chronic weight management in adults with obesity (or overweight with comorbidities). Reuters But the stock story is bigger than a single approval. Heading into 2026, Novo’s equity narrative is being rewritten around three questions:
25 December 2025
·
Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly Stock (LLY) News on Dec. 24, 2025: GLP‑1 Pill Rivalry, India Expansion, and the Latest Analyst Forecasts

Eli Lilly and Company (NYSE: LLY) stock is in the spotlight on December 24, 2025 (Christmas Eve) as investors digest a new round of GLP‑1 headlines that span regulatory momentum, global market expansion, and shifting coverage expectations—all of which feed directly into the long-term demand outlook for Lilly’s obesity and diabetes franchise. In a shortened U.S. trading session—with NYSE and Nasdaq closing early at 1:00 p.m. ET—LLY shares traded modestly higher in morning action, with lighter volume typical of holiday weeks. New York Stock Exchange+1 Eli Lilly stock price today (NYSE: LLY) — Christmas Eve trading snapshot As of the
24 December 2025
···
Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Novo Nordisk Stock (NVO) in Focus on Dec. 24, 2025: Wegovy Pill Shockwave, Policy Tailwinds, and Analyst Forecasts

Dec. 24, 2025 — Novo Nordisk A/S (NYSE: NVO) has snapped back into the market’s spotlight this week after U.S. regulators cleared a pill version of its blockbuster obesity drug Wegovy—an approval that investors and analysts see as a pivotal moment in the fast-evolving GLP‑1 weight-loss race. But the story driving Novo Nordisk stock today is bigger than a single FDA decision: it’s also about pricing and coverage policy in the U.S., and a global expansion battle—especially in India—where branded GLP‑1s are colliding with the prospect of cheaper generics in 2026. Novo Nordisk+2Reuters+2 NVO shares have been trading around the
24 December 2025
···
Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly Stock (LLY) After Hours Today (Dec. 23, 2025): What Happened After the Bell—and What to Watch Before the Market Opens Dec. 24

Eli Lilly and Company (NYSE: LLY) ended Tuesday, December 23, 2025, modestly lower as investors digested a major competitive jolt in the booming obesity-drug market. LLY closed at $1,071.64, down about 0.45%, and was little changed in early after-hours trading. FinancialContent+1 The market’s attention today wasn’t on a fresh Lilly press release or an earnings surprise—it was on Novo Nordisk’s newly approved Wegovy pill, the first oral GLP‑1 cleared in the U.S. for chronic weight management. That approval, announced Monday and dominating headlines today, is reshaping near-term expectations for how the next phase of the GLP‑1 race will be fought:
23 December 2025
··
Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

Eli Lilly Stock (LLY) Today: Wegovy Pill Approval Raises the Stakes in GLP‑1s as Wall Street Forecasts Point to a High‑Expectation 2026

December 23, 2025 — Eli Lilly and Company stock (NYSE: LLY) is holding near record territory as investors digest a fresh twist in the weight-loss drug race: the FDA has cleared Novo Nordisk’s first oral version of Wegovy, intensifying competition right as Lilly pushes its own once-daily pill candidate, orforglipron, toward a potential 2026 approval. As of 15:11 UTC on Tuesday, LLY traded around $1,077, slightly above the prior close, after moving between roughly $1,057 and $1,088 during the session. The backdrop is simple but powerful: the obesity market is expanding fast, and the “next chapter” is about convenience, supply,
23 December 2025
···
Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

Novo Nordisk (NVO) Stock Jumps as FDA Approves Wegovy Weight-Loss Pill: Latest News, Forecasts, and What Investors Watch Next

December 23, 2025 — Novo Nordisk A/S (NYSE: NVO) is back in the spotlight after U.S. regulators approved a pill version of Wegovy, a milestone that could reshape the fast-growing obesity drug market—and potentially reset the narrative around a stock that’s had a bruising 2025. In U.S. trading on Dec. 23, Novo Nordisk shares traded around $52, up roughly 9% on the day, as investors digested what the approval means for market share, pricing power, and the competitive race with Eli Lilly. Reuters What happened to Novo Nordisk stock on Dec. 23, 2025? Novo Nordisk’s rally was driven by a
23 December 2025
·
Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

Eli Lilly Stock (LLY) Outlook on Dec. 23, 2025: Novo’s Wegovy Pill, Lilly’s Next Catalysts, and Wall Street Forecasts

December 23, 2025 — Eli Lilly and Company (NYSE: LLY) is trading around $1,076 as investors digest a fresh competitive jolt in the obesity-drug race: the FDA has approved Novo Nordisk’s first daily oral version of Wegovy. The headline is about Novo, but the market’s real question is about Lilly’s moat: can LLY keep dominating the category while a new “pill era” starts to form? Reuters+1 Why Eli Lilly stock is in focus today: the FDA just green-lit the first oral Wegovy On December 23, Novo Nordisk won U.S. approval for a 25 mg oral Wegovy pill (semaglutide) for chronic
23 December 2025
··
Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk A/S (NYSE: NVO) is back in the market’s spotlight on 23 December 2025 after a major regulatory milestone: the U.S. Food and Drug Administration approved a pill version of Wegovy, making it the first oral GLP‑1 receptor agonist cleared for chronic weight management in the U.S. The news sent Novo Nordisk shares sharply higher in early trading and reverberated across European markets, where the company’s move helped lift healthcare stocks. Novo Nordisk+2Reuters+2 The approval also lands at a delicate moment for Novo: competition from Eli Lilly has intensified, pricing pressure is building, and investors have been scrutinizing Novo’s
23 December 2025
···
FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

FDA Approves Wegovy Pill: Novo Nordisk’s Oral Semaglutide Launch Ignites a 2026 Weight‑Loss Drug Showdown

On December 22, 2025, Novo Nordisk won one of the most consequential regulatory decisions in modern obesity medicine: U.S. FDA approval of a once‑daily “Wegovy pill” (oral semaglutide 25 mg) for chronic weight management—marking the first oral GLP‑1 authorized in the U.S. specifically for weight loss. Novo Nordisk+1 For Novo Nordisk, the milestone is more than a product expansion. It’s a high‑stakes move to defend its GLP‑1 franchise, widen access beyond injections, and reassert momentum after a volatile year in which investors questioned its growth trajectory and competitive positioning. Reuters+1 What the FDA approved on December 22, 2025 The Wegovy
23 December 2025
··
Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly Stock (LLY) After Hours Drops on Wegovy Pill Approval: What to Know Before the Market Opens Dec. 23, 2025

Eli Lilly and Company (NYSE: LLY) ended Monday’s regular session higher — then slipped after the closing bell as investors digested a major late-day headline from its biggest obesity rival, Novo Nordisk. LLY closed at $1,076.48 (+0.47%) at 4:00 p.m. ET on Monday, Dec. 22, 2025, then traded down about 1% in after-hours action, around $1,065.50 as of 6:18 p.m. ET. StockAnalysis+1 That after-hours dip matters because the news that hit late Monday is exactly the kind of development that can reprice sentiment around the hottest corner of big pharma: GLP‑1 weight-loss drugs — and, increasingly, GLP‑1 pills. LLY stock
23 December 2025
····
Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly Stock (LLY) After Hours Today (Dec. 18, 2025): Orforglipron Headlines, Analyst Forecasts, and What to Watch Before Friday’s Open

Eli Lilly and Company (NYSE: LLY) finished Thursday’s session higher and held those gains in after-hours trading, as investors digested fresh late-stage data for its oral obesity candidate orforglipron—and weighed a second, potentially market-moving theme: pricing pressure and affordability initiatives. As of early evening after the closing bell, LLY was little changed in after-hours trading at $1,057.26 (+0.04%), after closing the regular session at $1,056.88 (+1.45%). Investing.com Below is what drove the stock today (Thursday, December 18, 2025)—and what investors should keep on the radar before the market opens Friday, December 19, 2025. LLY stock price check after the bell
18 December 2025
···
Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Novo Nordisk Stock (NOVO-B, NVO) Update Dec 14, 2025: Wegovy 7.2 mg Tailwind, Ozempic India Launch, Akero Deal — Outlook for the Week Ahead

Updated: December 14, 2025 (Sunday) Novo Nordisk A/S shares ended this week with a rebound after a choppy start, as investors weighed three heavyweight catalysts: (1) the EU regulator’s support for a higher-dose Wegovy, (2) the long-telegraphed India launch of Ozempic at a sharply lower price point, and (3) the closing of Novo’s multibillion-dollar acquisition of Akero Therapeutics to expand beyond obesity/diabetes into MASH (fatty liver disease). Reuters+2Reuters+2 While the broader 2025 narrative has been painful—Novo’s U.S. ADR is down roughly ~41% YTD by some market-data services, and Danish-listed shares have been down more than 50% at points this year—the
14 December 2025
····
Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Updated December 7, 2025 – for information only, not investment advice. Novo Nordisk stock today: from market darling to turnaround story Novo Nordisk (NYSE: NVO), the Danish giant behind GLP‑1 blockbusters Wegovy and Ozempic, has gone from Europe’s most valuable listed company to a bruised turnaround story in 2025. For investors, NVO has abruptly shifted from a “can do no wrong” growth icon to a complex mix of structural strengths (dominant GLP‑1 franchise, deep pipeline, global reach) and cyclical headaches (pricing pressure, competition, R&D setbacks). The Alzheimer’s shock: EVOKE and EVOKE+ miss their goal The biggest single blow of 2025
7 December 2025
··
Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk A/S stock is staging a sharp rebound today, 26 November 2025, as investors digest a trio of major developments: an FDA filing for a higher-dose version of its blockbuster obesity drug Wegovy, clarity on steep—but largely expected—Medicare price cuts for Ozempic and Wegovy, and fresh enthusiasm around its next‑generation obesity candidate amycretin. As of 20:48 UTC on 26 November 2025, Novo Nordisk’s U.S.-listed ADRs (ticker NVO) traded at $48.79, up about 3.7% on the day, with intraday trading between $46.79 and $49.02 and volume near 15 million shares. On its primary listing in Copenhagen, Novo Nordisk B shares
26 November 2025
···
1 2 3 4

Stock Market Today

China Construction Bank Class A stock ticks up at Friday close as China data looms

China Construction Bank Class A stock ticks up at Friday close as China data looms

7 February 2026
China Construction Bank Class A shares closed up 0.11% at 8.84 yuan in Shanghai on Friday, with around 100 million shares traded. The Shanghai Composite slipped 0.25%. Investors are watching for January inflation data on Feb. 11 and credit figures on Feb. 13 for policy signals. Premier Li Qiang called for early fiscal support to meet economic targets, state media reported.
PetroChina Class A stock rises with oil rebound — what 601857 traders watch next week

PetroChina Class A stock rises with oil rebound — what 601857 traders watch next week

7 February 2026
PetroChina A-shares rose 2.3% to 10.77 yuan Friday, outperforming the Shanghai Composite, which fell 0.25%. Crude prices rebounded, with Brent settling at $68.05 a barrel, as traders tracked U.S.-Iran talks and new EU sanctions proposals. About 198.5 million PetroChina shares traded in the session. Investors await the company’s next earnings report later this quarter.
Morgan Stanley stock price bounces after three-day slide; what to watch before Monday

Morgan Stanley stock price bounces after three-day slide; what to watch before Monday

7 February 2026
Morgan Stanley shares rose 2.34% to $179.96 Friday, snapping a three-day slide as the Dow closed above 50,000 for the first time. About 9.1 million MS shares traded hands. The rebound followed Thursday’s 2.35% drop and came amid renewed rate-cut speculation and surging AI spending. Morgan Stanley remains 6.6% below its January high.
Go toTop